구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Toripalimab + cetuximab (3cycles, 3cycles (Toripalimab + cetuximab)) Eli Lilly / Merck KGaA·Head and Neck Squamous Cell Carcin… 29 trials |
|---|---|
Overview Program | 3cycles (Toripalimab + cetuximab) |
Overview Company | Eli Lilly / Merck KGaA |
Overview Modality | ANTIBODY |
Overview Target | Head and Neck Squamous Cell Carcinoma |
Overview Indication | Head and Neck Squamous Cell Carcinoma; Neoadjuvant Therapy |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | No protection of heart, kidneys and brain by remote ischemic preconditioning before transfemoral transcatheter aortic valve implantation: Interim-analysis of a randomized single-blinded, placebo-controlled, single-center trial.. Remote ischemic preconditioning (RIPC) reduces myocardial injury and improves clinical outcome in patients undergoing coronary revascularization, but only in the absence o… |
Clinical Safety signal | No protection of heart, kidneys and brain by remote ischemic preconditioning before transfemoral transcatheter aortic valve implantation: Interim-analysis of a randomized single-blinded, placebo-controlled, single-center trial.. Remote ischemic preconditioning (RIPC) reduces myocardial injury and improves clinical outcome in patients undergoing coronary revascularization, but only in the absence o… |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Toripalimab + cetuximab (3cycles, 3cycles (Toripalimab + cetuximab)) Eli Lilly / Merck KGaA·Head and Neck Squamous Cell Carcin… 29 trials |
|---|---|
Overview Program | 3cycles (Toripalimab + cetuximab) |
Overview Company | Eli Lilly / Merck KGaA |
Overview Modality | ANTIBODY |
Overview Target | Head and Neck Squamous Cell Carcinoma |
Overview Indication | Head and Neck Squamous Cell Carcinoma; Neoadjuvant Therapy |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | No protection of heart, kidneys and brain by remote ischemic preconditioning before transfemoral transcatheter aortic valve implantation: Interim-analysis of a randomized single-blinded, placebo-controlled, single-center trial.. Remote ischemic preconditioning (RIPC) reduces myocardial injury and improves clinical outcome in patients undergoing coronary revascularization, but only in the absence o… |
Clinical Safety signal | No protection of heart, kidneys and brain by remote ischemic preconditioning before transfemoral transcatheter aortic valve implantation: Interim-analysis of a randomized single-blinded, placebo-controlled, single-center trial.. Remote ischemic preconditioning (RIPC) reduces myocardial injury and improves clinical outcome in patients undergoing coronary revascularization, but only in the absence o… |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교